Stephane Bancel - Mar 3, 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role: Chief Executive Officer, Director
Signature: /s/ James Dillon, as Attorney-in-Fact
Stock symbol: MRNA
Transactions as of: Mar 3, 2025
Transactions value $: $5,004,318
Form type: 4
Date filed: 3/4/2025, 04:27 PM
Previous filing: Mar 3, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Purchase	$3.19M	+103K	+1.14%	$31.04	9.15M	Mar 3, 2025	See Footnote	F1, F2, F3
transaction	MRNA	Common Stock	Purchase	$1.81M	+57.5K	+0.63%	$31.53	9.21M	Mar 3, 2025	See Footnote	F1, F3, F4
holding	MRNA	Common Stock						5.49M	Mar 3, 2025	Direct
holding	MRNA	Common Stock						6.56M	Mar 3, 2025	See Footnote	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 represent open market purchases of 160,314 shares of the Issuer's common stock, totaling $5,005,040, by Boston Biotech Ventures, LLC ("Boston Biotech Ventures"), of which the Reporting Person is the majority equity unit holder and the sole managing member.
F2	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $30.38 to $31.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
F3	These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F4	The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $31.39 to $31.96. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.
F5	These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.